Premium
Time efficacy of a single dose of montelukast on exercise‐induced asthma in children
Author(s) -
Peroni Diego G.,
Piacentini Giorgio L.,
Ress Michela,
Bodini Alessandro,
Loiacono Attilio,
Aralla Raffaele,
Boner Attilio L.
Publication year - 2002
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1034/j.1399-3038.2002.02078.x
Subject(s) - montelukast , medicine , placebo , bronchoconstriction , asthma , dosing , crossover study , exercise induced asthma , anesthesia , alternative medicine , pathology
The aim of this study was to evaluate the timing of onset and the duration of action of a single oral‐dose treatment with montelukast in comparison to placebo on exercise‐induced asthma (EIA) in asthmatic children. Nineteen children (7–13 years) with stable asthma were evaluated. Patients undertook three consecutive treadmill exercise tests, respectively, 2, 12 and 24 h after a single‐dose administration. A double‐blind randomized, single‐dose, placebo‐controlled, crossover design was used. To assess bronchoconstriction after the exercise challenge, the maximal percentage fall in FEV 1 (ΔFEV 1 ) from the baseline value was considered. Two hours after dosing, ΔFEV 1 was −15.33 ± 2.93 for placebo and −13.33 ± 2.03 for montelukast. At 12 h, ΔFEV 1 was −18.69 ± 2.83 for placebo, −9.78 ± 1.85 for montelukast (p < 0.005). No difference was observed between placebo (ΔFEV 1 −10.21 ± 2.07) and montelukast (ΔFEV 1 −9.10 ± 2.02) at 24 h. Analysis of the degree of protection showed a significant efficacy of montelukast (p = 0.02) in comparison with placebo only at 12 h. Montelukast showed a significant protective effect 12 h after dosing, but no effect after 2 and 24 h. In mild asthmatics, the timing of administration of single dosage before exercise should be strictly considered in order to obtain the drug protective effects.